menu search

KYMR / Kymera Therapeutics, Inc. (KYMR) Q3 2023 Earnings Call Transcript

Kymera Therapeutics, Inc. (KYMR) Q3 2023 Earnings Call Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q3 2023 Earnings Call Transcript November 2, 2023 8:00 AM ET Company Participants Justine Koenigsberg - VP, IR Nello Mainolfi - Founder, President and CEO Jared Gollob - CMO Bruce Jacobs - CFO Conference Call Participants Brad Canino - Stifel Gospel M. Enyindah-Asonye - Morgan Stanley Marc Frahm - TD Cowen Eric Joseph - JPMorgan Srikripa Devarakonda - Truist Securities Derek Archila - Wells Fargo Chris Shibutani - Goldman Sachs Kalpit Patel - B. Read More
Posted: Nov 4 2023, 13:10
Author Name: Seeking Alpha
Views: 062391

KYMR News  

Kymera Therapeutics, Inc. (KYMR) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 4, 2023

Kymera Therapeutics, Inc. (KYMR) Q3 2023 Earnings Call Transcript

Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q3 2023 Earnings Call Transcript November 2, 2023 8:00 AM ET Company Participants Justine Koenigsberg - VP, I more_horizontal

Kymera Therapeutics, Inc. (KYMR) Loses -33.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

By Zacks Investment Research
October 19, 2023

Kymera Therapeutics, Inc. (KYMR) Loses -33.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Kymera Therapeutics, Inc. (KYMR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong more_horizontal

Kymera Therapeutics, Inc. (KYMR) Loses -35.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

By Zacks Investment Research
October 18, 2023

Kymera Therapeutics, Inc. (KYMR) Loses -35.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Kymera Therapeutics, Inc. (KYMR) as it is technically in oversold territory now. In addition to th more_horizontal

Kymera Therapeutics, Inc. (KYMR) Soars 14.3%: Is Further Upside Left in the Stock?

By Zacks Investment Research
October 4, 2023

Kymera Therapeutics, Inc. (KYMR) Soars 14.3%: Is Further Upside Left in the Stock?

Kymera Therapeutics, Inc. (KYMR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings more_horizontal

Why Shares of Kymera Therapeutics Jumped on Tuesday

By The Motley Fool
October 3, 2023

Why Shares of Kymera Therapeutics Jumped on Tuesday

Kymera Therapeutics has nine programs in its pipeline. It has a collaboration with Sanofi on its lead therapy IRAK-4. more_horizontal

Kymera Therapeutics - Need More Developments Before Making This A Buy

By Seeking Alpha
August 9, 2023

Kymera Therapeutics - Need More Developments Before Making This A Buy

Kymera Therapeutics' valuation is difficult to estimate due to lack of positive net income, making it a poor buy. The company received FDA Orphan Drug more_horizontal

Perella Weinberg Partners (PWP) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 6, 2023

Perella Weinberg Partners (PWP) Q2 2023 Earnings Call Transcript

Perella Weinberg Partners (PWP) Q2 2023 Earnings Conference Call August 3, 2023 9:00 AM ET Company Participants Bruce Jacobs - CFO Nello Mainolfi - Fo more_horizontal

Kymera: More Data Needed

By Seeking Alpha
May 14, 2023

Kymera: More Data Needed

Kymera produced solid-looking phase 1 data, but Pfizer's problems in the space, along with some safety issues, hurt its stock. When partner Sanofi pro more_horizontal


Search within

Pages Search Results: